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Abstract
Background:  Scavenger receptors (SRs) recognize endogenous molecules modified by
pathological processes as well as components of diverse microorganisms. Mice deficient for both
SR-AI and II are more susceptible to infections by a variety of bacterial and viral pathogens.
Results: Here we show that SR-A deficient mice and wild type mice are equally susceptible to
malaria infection both during liver and blood stages. Moreover, like wild type mice, SR-A deficient
mice are able to mount a protective immune response against radiation attenuated sporozoites.
Conclusion: Our results do not reveal a function of SR-A I and II receptors in the Plasmodium
berghei ANKA infection, both in the development of CM and parasitemia control. Moreover, these
receptors appear not to be required for the establishment of a protective immune response against
the malaria liver stages.
Background
Malaria infection starts in the mammalian host with the
injection of Plasmodium sporozoites by a mosquito bite.
Sporozoites travel to the liver where they cross the sinusoi-
dal wall through Kupffer cells and then migrate through
several hepatocytes before they establish an infection with
the formation of a parasitophorous vacuole [1,2]. Within
the vacuole the sporozoites develop and generate millions
of merozoites that are released into the bloodstream. With
the infection of erythrocytes the clinical phase of malaria
begins. In any given year, more than a million children die
as a result of malaria infection. The death from infection
is largely due to an acute syndrome known as cerebral
malaria (CM). The neurological manifestations of CM
include headache, agitation, psychosis, seizures and
impaired consciousness that lead to coma and death [3].
The class A macrophage scavenger receptor (SR-A) is the
prototypic member of a large family of membrane recep-
tors that bind oxidized low density lipoprotein and a wide
variety of other ligands many of which are derived from
apoptotic cells and pathogens [4]. The SR-A receptors
occur in two different forms that are generated by alterna-
tive splicing of the primary transcript: SR-AI and SR-AII.
Both receptors have nearly identical ligand binding prop-
erties [4]. They are expressed primarily by mature cells of
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the myelomonocytic lineage such as Kupffer cells in the
liver, glial cells in the brain and macrophages that are res-
ident in or recruited to various tissues. They are also
expressed by sinusoidal endothelial cells in the liver [5].
SR-A receptors appear to have beneficial and pathological
functions. They mediate phagocytosis of apoptotic cells
[6], and have been implicated in atherogenesis, the clear-
ance of debris during acute neuronal degeneration [7] as
well as in innate immunity and antigen presentation [6].
SR-A receptors bind lipopolysaccharide from Gram-nega-
tive and lipoteichoic acid from Gram-positive bacteria [4].
SR-AI and II receptor deficient mice (SR-A-/-) are more sus-
ceptible to infections by a variety of pathogenic microor-
ganisms such as Listeria monocytogenes [8], Staphylococcus
aureus [9], Bacillus Calmette-Guérin [10] and herpes sim-
plex virus [8].
In the present work we examined the role of SR-A recep-
tors in three different aspects of a malaria infection,
namely first, in the establishment of a primary liver infec-
tion; second, in the protective immune response against
the liver stages; and third, in the development of the cere-
bral pathology associated with blood stages of infection.
Results and discussion
The initial targeting of sporozoites to the liver involves
close interactions with sinusoidal endothelial cells and
Kupffer cells [2], both of which express SR-AI and SR-AII
receptors. To study the possible involvement of these
receptors in the initial stages of malaria infection we
infected SR-A-/- mice as well as their SR-A+/+ littermates [8]
with 2 × 104 Plasmodium berghei ANKA sporozoites. The
parasite burden in the liver was measured 40 hours after
infection, just prior to the release of merozoites into the
bloodstream. The level of infection was determined by
quantitative RT-PCR (qRT-PCR) using specific primers for
Plasmodium berghei 18s ribosomal RNA [11]. There was no
difference in the level Plasmodium berghei ANKA infection
in SR-A-/- mice, when compared to SR-A+/+ mice (Fig. 1A).
SR-A receptor functions have been implicated in both the
innate and the adaptive branches of the immune
response. To determine whether SR-A receptors play a role
in immune responses against malaria, we used a well-
established model of immunization against the liver
stages of malaria infection. Inoculation with radiation
attenuated sporozoites (RAS) results in protection against
a subsequent challenge with infective sporozoites, both in
mice and humans [12,13]. Irradiated sporozoites invade
hepatocytes but do not develop normally and thus fail to
establish an erythrocytic infection [14]. SR-A-/- mice as
well as their SR-A+/+ littermates [8] were immunized with
5 × 104 Plasmodium berghei RAS and challenged 10 days
later with 104 infective sporozoites. Forty two hours after
the challenge the level of protection was measured by
quantifying the parasite load in the liver using qRT-PCR,
as described above. RAS immunization of SR-A+/+ mice, as
expected, clearly reduced the level of infection measured
40 hours after a challenge with infective sporozoites. The
same level of protection was achieved in SR-A-/- mice (Fig.
1B). This shows that the lack of SR-A receptors does not
Lack of SR-A expression does not affect Plasmodium berghei  liver infection Figure 1
Lack of SR-A expression does not affect Plasmodium 
berghei liver infection. (A) Plasmodium berghei quantifica-
tion in the liver 40 hours post infection with Plasmodium 
berghei ANKA sporozoites as measured by qRT-PCR. (B) 
Plasmodium berghei quantification in the liver 40 hours post 
challenge with 10,000 Plasmodium berghei ANKA sporozoites, 
in animals previously immunized with a single dose of 50,000 
radiation attenuated Plasmodium berghei ANKA sporozoites 
(RAS), as measured by qRT-PCR. Shown is the mean number 
of Plasmodium berghei ANKA 18s per HPRT mRNA mole-
cules (×103) ± standard deviation (n = 4 mice per plot). 
Experiments were repeated twice.
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affect the establishment of a protective immune response
against RAS.
The molecular and cellular mechanisms that lead to the
devastating symptoms of CM remain poorly understood.
The disease is associated with enhanced adherence of
infected erythrocytes to the cerebral vasculature, disrup-
tion of the blood-brain barrier, activation and prolifera-
tion of migroglial cells, expression and secretion of
proinflammatory molecules, and recruitment of macro-
phages and other inflammatory cells to the primary
lesions. SR-AI and II receptors are expressed by both acti-
vated macrophages and glial cells. They could have dis-
ease promoting or protective functions. Infection of
C57BL/6 mice with Plasmodium berghei ANKA is a well-
established experimental model of malaria infection.
When infected with Plasmodium berghei ANKA, C57BL/6
mice develop neurological disturbances such as hemi- or
paraplegia, deviation of the head, tendency to roll over on
stimulation, ataxia and convulsions and die between days
6 to 9 post-infection [15]. Due to the many similarities
with human CM this neurological syndrome is referred to
as experimental CM (ECM) (reviewed in [15]). Still, cau-
tion should be taken when extrapolating from the rodent
model to the human disease. While human CM is pre-
dominantly associated with iRBC adherence to the micro-
vasculature of the brain, mouse brains infected with P.
berghei  ANKA (and showing symptoms of ECM) show
blood brain vessel congestion containing mainly leuco-
cytes and low level of iRBCs. Despite these differences, the
altered cells that play a pivotal role in human and rodent
lesions during malaria infection are the same, the brain
microvascular endothelial cells. We inoculated both SR-A-
/- mice and their SR-A+/+ littermates in C57BL/6 back-
ground with 106 Plasmodium berghei ANKA infected eryth-
rocytes. All mice in both groups developed neurological
symptoms and died between 6 to 8 days after infection
(Fig. 2A). There were no significant differences in the level
of parasitemia between the 2 groups (Fig. 2B). The results
were similar when infection was initiated with 2 × 104
sporozoites and allowed to proceed for blood stages (data
not shown). This finding is in agreement with a short
report by Nogami et al. who found the same levels of par-
asitemia in SR-A deficient and wild type mice after inocu-
lation with erythrocytes that were infected with
Plasmodium berghei NK65, an experimental model that
does not induce CM [16]. In that study only 1 out of 8 SR-
A+/+ mice died on day 10, while in the group 2 out of 8
mice died on day 7 and a further 3 mice died on day 17.
Since these deaths coincided with the two peaks of para-
sitemia, the authors suggested that SR-A-/- mice might
have more difficulty in controlling peaks of parasitemia.
Thus, we sought to determine the role of SR-A in the
course of infection of a non-lethal malaria rodent model,
P. yoelii 17×. In this model, wild-type mice produce a peak
of parasitemia around day 10 post-infection and are able
to control it with 100% survival and full parasite clear-
ance. SR-A-/- infected in parallel showed no difference in
survival or parasitemia during the course of infection
(data not shown), again in agreement with the results very
recently published by Inoue et al. [17].
Taken together our data suggests that the lack of SR-A
receptors has no influence in the malaria outcome during
the blood stages of infection.
Conclusion
The results shown here do not reveal a function of SR-A I
and II receptors in the Plasmodium berghei ANKA infection,
in the development of CM or parasitemia control. Moreo-
ver, these receptors appear not to be required for the
Lack of SR-A expression does not affect Plasmodium berghei  infection and its associated pathology Figure 2
Lack of SR-A expression does not affect Plasmodium 
berghei infection and its associated pathology. Survival 
(A) and parasitemia (B) of SR-A-/- and SR-A+/+ mice infected 
with 106 Plasmodium berghei ANKA infected red blood cells. 
Mean ± standard deviation (n = 4 mice per plot) is shown for 
parasitemias. Experiment repeated 3 times.
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establishment of a protective immune response against
the malaria liver stages in the well-established model of
immunity against RAS. It has been shown that mice defi-
cient in another member of the scavenger receptor family,
CD36, have no differences at the liver infection [18].
Moreover, recent experiments with mice deficient in
CD36, indicate that this receptor is involved in the seques-
tration of Plasmodium berghei ANKA to the lung and adi-
pose tissues but not in the development of cerebral
malaria [19]. In view of the complex and overlapping
functions of different scavenger receptors it is conceivable
that the true role of individual receptors is not revealed in
experiments with receptor deficient mice unless a specific
function of the receptor is analyzed [6]. Whether SR-A
receptors do have such specific functions in malaria infec-
tions of mice or humans remains to be elucidated.
Methods
Infection
Plasmodium berghei ANKA sporozoites were obtained from
dissection of infected Anopheles stephensi mosquito sali-
vary glands from the IMM insectary production. Male, 7–
9 weeks old, SR-A-/- and their control littermate mice gen-
erously provided by Dr. T. Kodama (University of Tokyo)
[8] were infected by intravenous injection of Plasmodium
berghei (2 × 104) sporozoites or by intraperitoneal injec-
tion of Plasmodium berghei ANKA or P. yoelii 17 × (106)
infected erythrocytes (originally, provided by Dr. A.
Waters and C. Janse, Leiden University, or Dr. David Wal-
liker, Edimburgh University, respectively).
Parasite quantification in the liver
40 hours post infection with sporozoites livers were
removed, homogenized and total RNA was extracted
(RNeasy Mini kit Quiagen). cDNA was obtained by
reverse transcription (First-strand cDNA synthesis kit,
Roche). Real-time PCR, using primers specific for Plasmo-
dium berghei 18S rRNA (5'-AAGCATTAAATAAAGCGAAT-
ACATCCTTAC-3' and 5'-
GGAGATTGGTTTTGACGTTTATGTG-3'), was used for
quantification of parasite load in the livers of mice 40
hours after sporozoite inoculation.
Immunization protocol
Immunizations with radition attenuated sorozoites was
perfomed by injecting 5 × 104 γ-irradiated (16,000 rads)
Plasmodium berghei ANKA sporozoites followed by chal-
lenge (10 days later) with 104 infective sporozoites, both
by intravenous injection. Parasite burden in the liver was
measured as described in the previous section.
Following blood stage infection and pathology
Cerebral complications were monitored by ataxia, paraly-
sis, deviation of the head and convulsions, symptoms
leading to coma and death. Blood peripheral parasitemia
was determined by counting parasites in Giemsa stained
thin blood films.
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